X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/eisai-to-present-preclinical-and-clinical-research-on-eribulin-at-the-2022-san-antonio-breast-cancer-symposium-301690865.html
https://www.fiercebiotech.com/biotech/winner-crowned-head-head-battle-between-lilly-and-biogens-alzheimers-drugs
https://endpts.com/as-competitors-near-fda-goalpost-roche-spells-out-its-repeat-alzheimers-setback/
https://www.reuters.com/business/healthcare-pharmaceuticals/eisai-biogen-alzheimers-drug-could-be-available-some-next-year-2022-11-30/
https://www.europeanpharmaceuticalreview.com/news/176966/nejm-publishes-lecanemab-alzheimers-study-results/
https://www.fiercebiotech.com/biotech/eisai-biogen-rocked-second-alzheimers-death-report-ahead-lecanemab-data-reveal
https://endpts.com/eisais-expanded-alzheimers-data-leave-open-questions-about-safety-and-clinical-benefit/
https://www.prnewswire.com/news-releases/eisai-to-present-latest-data-on-fycompa-perampanel-ciii-at-the-76th-american-epilepsy-society-aes-annual-meeting-301685641.html
https://www.prnewswire.com/news-releases/eisai-to-present-full-findings-from-lecanemab-confirmatory-phase-3-clinical-trial-clarity-ad-and-other-alzheimers-disease-research-at-the-15th-clinical-trials-on-alzheimers-disease-ctad-conference-301683436.html
Market Place
Share 
